Mesothelioma

A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)

Also Known As:

Networked: 6463 relevant articles (293 outcomes, 981 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Adenocarcinoma
3.	Carcinoma (Carcinomatosis)
4.	Malignant Mesothelioma
5.	Lung Neoplasms (Lung Cancer)

Experts

1.	Carbone, Michele: 58 articles (01/2022 - 02/2002)
2.	Pass, Harvey I: 58 articles (01/2022 - 02/2002)
3.	Hassan, Raffit: 55 articles (01/2022 - 11/2002)
4.	Nowak, Anna K: 43 articles (01/2022 - 02/2002)
5.	Bueno, Raphael: 42 articles (10/2022 - 05/2002)
6.	Marinaccio, Alessandro: 42 articles (01/2022 - 05/2003)
7.	Pastan, Ira: 41 articles (01/2022 - 06/2002)
8.	Mensi, Carolina: 40 articles (01/2022 - 07/2004)
9.	Creaney, Jenette: 39 articles (01/2022 - 11/2003)
10.	Mirabelli, Dario: 38 articles (01/2022 - 07/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Mesothelioma:

1.	Pemetrexed (MTA)FDA Link 04/01/2013 - "Pemetrexed has been approved with an anti-mesothelioma drug and was confirmed to be effective for NSCLC. " 10/01/2009 - "Survey and biological insights of pemetrexed-related therapeutic improvement in mesothelioma: The Nancy Centre of Biological Resources' Mesothelioma Cohort." 11/01/2006 - "Efficacy of a combination of pemetrexed and multiple redo-surgery in an 11-year-old girl with a recurrent multifocal abdominal mesothelioma." 12/01/2023 - "This was a cooperative group, single-arm, phase 2 trial enrolling patients with unresectable mesothelioma after progression on more than or equal to one pemetrexed-containing regimen. " 02/01/2018 - "F-FDG PET/CT and DCE-MRI studies carried out as part of the South West Area Mesothelioma Pemetrexed trial were used. "
2.	Cisplatin (Platino)FDA LinkGeneric 06/01/2010 - "Since it has been recently suggested that Mcl-1 cooperates with Bcl-x(L) for protection against cell death, we investigated the response of mesothelioma cell lines to the downregulation of Bcl-x(L) (alone or in combination with cisplatin) and the potential interest of its concomitant inhibition with that of Mcl-1. " 02/01/2013 - "The findings of the present study provide insights into cisplatin-induced mechanisms in mesothelioma cells and show that alternative pathways are operating which may provide new options for targeting this extremely resistant tumour." 02/01/2013 - "In this study, we examined cisplatin-induced cell death pathways and IAPs in three mesothelioma-derived cell lines. " 04/01/2006 - "Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma." 07/01/1995 - "In a previous phase II study with a dose-intensive weekly cisplatin schedule for six cycles, we observed a partial response in 5 of 14 patients with pleural mesothelioma. "
3.	AsbestosIBA 11/01/2020 - "Paediatric mesothelioma is exceptional and seems to be different from its adult counterpart with few asbestos exposures, more peritoneal primary, and a better outcome. " 01/01/2022 - "Exposure assessment was performed: (1) through experts' evaluation (considered as the gold standard for the purpose of this study), according to the guidelines of the Italian National Mesothelioma Registry (ReNaM) and (2) using a job-exposure matrix (SYN-JEM) to obtain qualitative (ever/never) and quantitative estimates of occupational asbestos exposure (cumulative exposure expressed in fibers per mL (f/mL)). " 08/15/2008 - "Some authors have suggested that the increase in mesothelioma rate with TSFE might be attenuated by clearance of asbestos from the lungs. " 01/01/2008 - "Mesothelioma mortality was based on cumulative exposure and time since first exposure, with the inclusion of a term for clearance of asbestos fibres from the lung. " 07/01/2007 - "However, some authors have suggested that the increase in mesothelioma rate with TSFE might be attenuated by clearance of asbestos from the lungs. "
4.	AntibodiesIBA 01/01/2011 - "This panel of antibodies may be helpful in establishing a pathologic diagnosis of sarcomatoid mesothelioma. " 02/15/2009 - "As the first step in evaluating the therapeutic potential of MCAM-targeting antibodies, we performed single-photon emission computed tomography studies using the anti-MCAM scFv and found that it recognizes mesothelioma organotypic xenografts in vivo. " 05/01/2006 - "The study showed that mesothelial marker antibodies commonly used in human patients can be used for the diagnosis of feline mesothelioma, preferably as a panel of antibodies rather than only one." 10/01/1991 - "To determine the origin of a mesothelioma of the atrioventricular node, immunohistochemical studies that used various antibodies, including the antibody against mesothelial cells, were performed on a mesothelioma of the atrioventricular node in a case. " 01/01/2021 - "The in vitro properties of radiolabeled antibodies were evaluated by cell binding and competitive inhibition assays using PDPN-expressing H226 mesothelioma cells. "
5.	PlatinumIBA 02/01/2022 - "Treatment of Platinum Nonresponsive Metastatic Malignant Peritoneal Mesothelioma With Combination Chemoimmunotherapy." 12/01/2018 - "An overview of the interactions between platinum drugs and non-coding RNAs is given and the influence of non-coding RNAs on platinum drug efficacy in mesothelioma is discussed. " 12/01/2018 - "Relations between approved platinum drugs and non-coding RNAs in mesothelioma." 05/01/2009 - "PEM with or without a platinum agent was both active and well tolerated in patients with peritoneal mesothelioma." 11/01/2010 - "The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma."
6.	MesothelinIBA 08/01/2023 - "High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma." 01/01/2013 - "The new molecule, SS1-LR/GGS/8M, has cytotoxic activity comparable with SS1P on several mesothelin-expressing cell lines and remarkably improved activity on primary cells from patients with mesothelioma. " 10/12/2021 - "In the present study, we focussed on the differential glycosylation between ERC/mesothelin present on epithelioid mesothelioma and that on normal mesothelial cells and aimed to reveal a distinct feature of epithelioid mesothelioma cells. " 07/01/2021 - "Immunohistochemical studies revealed the lesional cells to be positive for WT1, mesothelin, D2-40, CK5/6, while being negative for melanocytic and other keratinocytic markers, supporting a diagnosis of metastatic mesothelioma. " 07/16/2020 - "We performed studies using the overexpression or knockdown of ERC/mesothelin in mesothelioma cells to examine its effect on cellular morphology, growth kinetics, or migration/invasion activity, in vitro. "
7.	Proteins (Proteins, Gene)FDA Link 10/01/2023 - "The aim of this study was to investigate the contribution of BRCA1-associated protein (1) (BAP1) loss and p16 (CDKN2A) homozygous deletion (HD) on the early diagnosis of mesothelioma in effusion fluids. " 09/01/2023 - "Preclinical studies have identified synthetic lethal protein and metabolic interactions, recurrently overexpressed proteins, and frequent pathway perturbations that may be therapeutically exploited in mesothelioma. " 02/01/2014 - "In this study, to identify an unknown protein with 120 kDa expressed only in the mesothelioma cell line 211H, we conducted proteomic analysis and found five candidate proteins. " 05/01/2012 - "Present study suggests that SFK inhibitors induce caspase-8-dependent apoptosis caused by reduction of Lyn protein in Fyn-deficient mesothelioma cells." 01/01/2008 - "This study tested the hypothesis that reexpression of p16INK4a carried out using the TAT delivery system that carries the protein transduction domain of the HIV TAT will result in mesothelioma cell death. "
8.	Biomarkers (Surrogate Marker)IBA 08/01/2008 - "The purpose of the current study was to directly compare these biomarkers in the same sample population, determining their sensitivity and specificity in establishing a diagnosis, and to determine if diagnostic accuracy for mesothelioma is improved by combining the data from all three markers. " 04/18/2023 - "Extracellular vesicles (EVs) have great potential as biomarkers; however, there are limited studies to date on their role in pleural mesothelioma. " 12/13/2022 - "By adopting "pleural mesothelioma" as our clinical model we summarize the most relevant pertinent and available literature on this topic, and use an analysis of the reliability of the trials submitted for registration and/or recently published as a case in point to raise concerns with respect to appropriate trial design, biomarker based stratification and to highlight the ongoing need for balancing the benefit/cost ratio for both patients and healthcare providers." 01/25/2022 - "An imaging databank will be assembled for validation of radiological measures of response, and studies of possible radiomic biomarkers in mesothelioma. " 09/01/2020 - "In addition, enrolling patients in window-of-opportunity trials of ICB in resectable mesothelioma and biomarker-focused correlative studies will be critical to furthering the mechanistic understanding of ICB in mesothelioma, which in turn will help to uncover biomarkers of response and resistance in these patients."
9.	AntigensIBA 03/26/2021 - "Here, to overcome inhibition, we determined the potential of recombinant adeno-associated virus (rAAV)-vectored, PD1-based vaccination in the tumor microenvironment (TME) to activate antigen-specific T cell responses in the immune-competent murine mesothelioma model. " 10/01/2018 - "The 5T4 antigen is expressed in mesothelioma and 5T4-based ADCs are internalized in lysosomes. " 10/01/2018 - "Expression of the 5T4 antigen is evaluated in (primary) mesothelioma cell lines and biopsy specimens, and correlated with clinical outcome. " 01/01/2015 - "There was positive immunohistochemical staining of mesothelioma-associated antigens. " 08/12/2013 - "Additionally, FAP-specific re-directed T cells lysed FAP positive mesothelioma cells and inflammatory fibroblasts in an antigen-specific manner in vitro. "
10.	GemcitabineFDA Link 02/01/2002 - "The role of single-agent gemcitabine in patients with mesothelioma is unclear, since three phase II trials treated a total of 60 patients and achieved response rates of 0%, 7%, and 31%. " 02/01/2021 - "Gemcitabine treatment was associated with widespread effects on circulating immune cells of mesothelioma patients with responding patients displaying increased NK-cell and PD-1 + T-cell proliferation. " 02/01/2021 - "We stained peripheral blood mononuclear cells (PBMCs) and myeloid-derived suppressor cells (MDSCs) at baseline and 3 weeks following start of gemcitabine or BSC treatment in a subgroup of mesothelioma patients included in the NVALT19-trial. " 02/01/2021 - "Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response." 12/15/2018 - "Furthermore, treatment with gemcitabine plus anti-PD-1 resulted in an objective clinical response in two patients with mesothelioma, who were resistant to gemcitabine or anti-PD-1 as monotherapy. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 12/01/2011 - "Although surgery is a gold standard for patients with early mesothelioma, most patients with advanced disease are not suitable for surgical resection and have option of palliative chemotherapy alone. " 02/01/1998 - "This is a case report of complete remission of malignant peritoneal mesothelioma by combined chemotherapy." 02/01/1998 - "A case of malignant peritoneal mesothelioma showed complete remission with chemotherapy." 11/15/1983 - "One patient with paratesticular mesothelioma metastatic to lungs entered complete remission for 8 months; his disease has relapsed but he is alive 32 months after initiation of chemotherapy. " 03/01/2009 - "Adjuvant treatment with chemotherapy or immuno-chemotherapy leads to significant reduction of mesothelioma recurrence after surgery in this rat MPM model. "
2.	Therapeutics 02/01/2008 - "A definitive and early diagnosis on effusion samples is important, because recent advances in therapy for patients with mesothelioma may result in an improved outcome if they are applied to stage I disease. " 02/10/2022 - "As the incidence of mesothelioma is still rising globally, novel treatment options based on a better understanding of the tumor microenvironment and the genetic drivers that modulate it are needed to support future precision-based therapies." 02/01/2018 - "Identification of clinically actionable ALK rearrangements may represent a novel pathogenetic mechanism of malignant peritoneal mesothelioma with promise for targeted therapy." 01/01/2018 - "Here, we used our well characterised mesothelioma tumour model to investigate the efficacy of different ICBP treatments to generate effective therapy for mesothelioma. " 01/01/2003 - "Our results suggest that adenoviral gene-based therapy, especially using Adp16INK4A-based strategy, may be effective in the treatment of human mesothelioma."
3.	Hyperthermic Intraperitoneal Chemotherapy 01/01/2010 - "Improved survival has been reported for diffuse malignant peritoneal mesothelioma (DMPM) treated by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). " 02/01/2009 - "Improved survival has been reported for diffuse malignant peritoneal mesothelioma (DMPM) treated by cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). " 01/01/2020 - "In this study, we evaluated QOL after HIPEC for peritoneal mesothelioma. " 01/01/2019 - "This study attempted to present the results of CRS in combination with hyperthermic intraperitoneal chemotherapy in patients with peritoneal mesothelioma and identify the prognostic indicators of survival. " 03/01/2015 - "When comparing survival results as well as morbidity-mortality rates, the present study shows that CRS and HIPEC-OX is a valid treatment for peritoneal mesothelioma."
4.	Immunotherapy 06/01/2006 - "Immunotherapy of mesothelioma might be more effective when combined with drugs that eliminate or control regulatory T-cells." 12/01/2019 - "Immunotherapy trials in mesothelioma - promising results, but don't stop here." 01/01/2023 - "Dendritic cell-based immunotherapy (DCBI) showed promising results in patients with pleural mesothelioma. " 12/14/2021 - "Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy." 01/01/2022 - "CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? "
5.	Cytoreduction Surgical Procedures 01/01/2016 - "Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for patients with malignant peritoneal mesothelioma has resulted in improved disease control and increased survival. " 12/01/2014 - "There are few studies addressing survival of diffuse peritoneal mesotheliomas (DPM).In this study, survival data were obtained retrospectively from 73 patients treated with intended cytoreductive surgery for DPM, with a mean follow-up of 42 months. " 06/01/2010 - "The history, clinical and laboratory data, and imaging studies of 13 patients with histologically proven diagnosis of Malignant Peritoneal Mesothelioma (MPM) and their recurrence following cytoreductive surgery were reviewed. " 02/01/2007 - "Recent phase I/II trials report encouraging results in selected patients with peritoneal mesothelioma (PM) treated with cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP). " 02/01/2023 - "The surgical management of pleural mesothelioma (PM) can be divided into diagnostic, staging, palliation, and cytoreductive surgery. "